Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/08/2007WO2007060208A3 Fast-dissolving isotropic expanded microporous composition or structure for pharmaceutical, veterinary, dietetic, food or cosmetic use and method for obtaining same
11/08/2007WO2007059482A3 Modulation of immune responses
11/08/2007WO2007056405A3 Magnesium-containing polymers for the treatment of hyperphosphatemia
11/08/2007WO2007056263A3 Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
11/08/2007WO2007056086A3 Rifamycin analogs and uses thereof
11/08/2007WO2007053620A3 Topical skin barriers and methods of evaluation thereof
11/08/2007WO2007052023A3 Novel compounds
11/08/2007WO2007051065A3 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
11/08/2007WO2007047416A3 Compositions and methods of administering rapamycin analogs with paclitaxel using medical devices
11/08/2007WO2007044829A3 Preparation of aprepitant
11/08/2007WO2007041388A3 Prevention and treatment of hearing disorders
11/08/2007WO2007038868A3 Novel enediyne compound and uses thereof
11/08/2007WO2007038801A3 Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
11/08/2007WO2007037874A3 Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear
11/08/2007WO2007035964A3 Vigabatrin bioisoteres and related methods of use
11/08/2007WO2007035828A3 Compositions and methods for preventing or treating encephalitis with interferon
11/08/2007WO2007035783A3 Combination formulations of cytidine analogs and platinum agents
11/08/2007WO2007035641A3 Palmarumycin based inhibitors of thioredoxin and methods of using same
11/08/2007WO2007022642A3 Anti-inflammatory molecules and their uses
11/08/2007WO2007021499A3 Antimicrobial polymers
11/08/2007WO2007020085A3 Compositions containing taxane derivatives for intravenous injection
11/08/2007WO2006133426A3 Compositions and methods for inhibition of the jak pathway
11/08/2007WO2006121767A3 4-aminoquinoline compounds for treating virus-related conditions
11/08/2007WO2006120360A3 Active composition for treatment or prevention of problems related to a disturbance of the biological clock
11/08/2007WO2006119148A3 Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis
11/08/2007WO2006107859A8 Dihydropyridine compounds for neurodegenerative diseases and dementia
11/08/2007WO2006106423A8 Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
11/08/2007WO2006095263A8 Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
11/08/2007WO2005122671A3 An improved process for the preparation of oxcarbazepine and related intermediates
11/08/2007WO2005115075A3 Salt of 4- or 5- aminosalicylic acid
11/08/2007WO2003013471A3 Pharmaceutical enteric coated composition comprising chitosan
11/08/2007WO2002022146A3 Components of canola for treating hyperlipidemia
11/08/2007WO2002022145A3 Components of canola for the treatment of cancer
11/08/2007WO2002012270A9 Peptides capable of functioning as mimotopes for estradiol analytes
11/08/2007US20070260299 Covalent Grafting of Hydrophobic Substances on Collagen
11/08/2007US20070260087 Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof
11/08/2007US20070260076 Efficient and inexpensive method to prepare ubiquinone precursors using benzenoid precursor with retention of the double bond stereochemistry; industrial scale
11/08/2007US20070260058 N-phenyl-1,3-thiazol-2-amine derivatives, useful in the treatment of neurodegenerative disorders, such as Alzheimer's disease
11/08/2007US20070260038 Preparation of microparticles having improved flow ability
11/08/2007US20070259969 Using CD44 expression profile as diagnostic indicator of cell proliferative disorders
11/08/2007US20070259967 Methods of Diagnosis
11/08/2007US20070259966 Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
11/08/2007US20070259964 reactants are more environmentally friendly, safe, less toxic to handle; reacion of 3-bromotrifluorotoluene with an allyl amine then reduction to give cinacalcet
11/08/2007US20070259963 N-[5-methanesulfonyl-4-(4-methanesulfonyl-3-pentafluorosulfanylphenoxy)-2-methyl-benzoyl]guanidine; diagnostic agents for hypertension, diabetes, proliferative disorders; inhibitors of the cellular sodium-proton antiporter (Na/H exchanger); good absorption, bioavailability; angina pectoris, infarction
11/08/2007US20070259962 Use of N-Arylhydrazine Derivatives for Combating Pests in and on Animals
11/08/2007US20070259961 Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthritis and in lowering blood glucose levels in animal or cancer
11/08/2007US20070259960 Compounds and methods for treatment of stroke
11/08/2007US20070259959 Ppar Agonists for the Treatment of Hcv Infection
11/08/2007US20070259958 Prevention of Neutrophil Recruitment
11/08/2007US20070259957 Jelly Composition
11/08/2007US20070259956 Compositions and methods for treating cancer
11/08/2007US20070259955 Process for the Preparation of Nateglinide
11/08/2007US20070259954 In particular, butyrates and formates of divalent metals, as well as their carboxylate-aminoate or carboxylate-methioninate hydroxy analog derivatives of divalent metals; use as trace metal supplements in animal feed; increasing bioavailability of metals, therefore reducing their emission to environment
11/08/2007US20070259953 2-methylene-19-nor-(23s)-25-dehydro-1alpha-hydroxyvitamin d3-26,23-lactone and 2-methylene-19-nor-(23r)-25-dehydro-1alpha-hydroxyvitamin d3-26,23-lactone
11/08/2007US20070259952 Uses of escitalopram
11/08/2007US20070259951 mitotic kinesins like KSP inhibitors; for treating cellular proliferative diseases; N-[(3-methyl-4'-trifluoromethyl)-4-biphenylyl]methanesulfonamide
11/08/2007US20070259950 Nebivolol and Its Pharmaceutically Acceptable Salts, Process for Preparation and Pharmaceutical Compositions of Nebivolol
11/08/2007US20070259949 broad spectrum antibiotic activity, in particular, Gram-positive bacteria
11/08/2007US20070259948 Compounds with antifungal properties and process thereof
11/08/2007US20070259947 Therapeutic compounds
11/08/2007US20070259946 N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane
11/08/2007US20070259945 Method for treating pain
11/08/2007US20070259944 Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents
11/08/2007US20070259943 Ortho-substituted pentafluorosulfanyl benzenes, method for the production thereof and their use as synthesis intermediates
11/08/2007US20070259942 Indolone derivatives like N2-[2-(5-Methyl-1H-3-indolyl)ethyl]-N4-(4-methylphenyl)-6-(1-piperidinyl)-2,4-pyrimidinediamine; galanin-type receptors; antidepressants; anxiolytic agents
11/08/2007US20070259941 Ramipril formulation
11/08/2007US20070259940 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
11/08/2007US20070259939 Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
11/08/2007US20070259937 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
11/08/2007US20070259936 Benzimidazole Modulators of VR1
11/08/2007US20070259935 Crystalline forms of letrozole and processes for making them
11/08/2007US20070259934 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
11/08/2007US20070259933 Compositions, dosage forms and methods of treating emesis
11/08/2007US20070259932 Benzimidazole derivatives, their production and use
11/08/2007US20070259931 Process of reducing the bitter taste of water soluble actives by co-grinding the acitve with beta cyclodextrin
11/08/2007US20070259930 Compositions and methods of using r(+) pramipexole
11/08/2007US20070259929 Therapeutic Compounds
11/08/2007US20070259928 Medicinal Composition for Treating Diabetes
11/08/2007US20070259927 Remedy for Diabetes
11/08/2007US20070259926 mGluR5 modulators III
11/08/2007US20070259925 Dpp iv inhibitors
11/08/2007US20070259924 such as 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide, used to prevent or treat conditions characterized by undesired thrombosis and inhibiting the coagulation of blood samples
11/08/2007US20070259923 MGluR5 modulators IV
11/08/2007US20070259922 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
11/08/2007US20070259921 Polymorphic forms of esomeprazole sodium
11/08/2007US20070259920 P2X7, receptor antagonists and uses thereof
11/08/2007US20070259918 2-Hydroxymethyl-3,4,5-Trihydroxy-1-(4-Pentyloxybenzyl) Piperidine as Glucosylceramide Synthase (Gcs) Inhibitor
11/08/2007US20070259917 Processes for the synthesis of 3-isobutylglutaric acid
11/08/2007US20070259916 mGluR5 modulators II
11/08/2007US20070259914 Novel Piperidine Derivates as Modulators of Chemokine Receptor Ccr5.
11/08/2007US20070259913 Prophylaxis of thromboembolic events in cancer patients
11/08/2007US20070259912 Polymorphic forms of a GABAA agonist
11/08/2007US20070259911 N-(6-tert.-Butyloxycarbonyl-3-cyano-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl)-benzamide; antiproliferative agent; anticarcinogenic agent
11/08/2007US20070259910 3-{4-[3-(2-Fluoro-5-trifluoromethylphenyl)ureido]phenyl}-1H-indole-2-carboxamide;KDR (Kinase insert Domain Receptor), Tie-2 and FAK tyrosine kinase receptor inhibitors; anticarcinogenic agents; psoriasis; antiinflammatory agents; antiarthritic agents; antidiabetic agents; Kaposi's sarcoma; hemangiomas
11/08/2007US20070259909 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors
11/08/2007US20070259908 Mitochondria Activators
11/08/2007US20070259907 Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
11/08/2007US20070259906 Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
11/08/2007US20070259905 silyl camptothecin derivatives for cancer and/or leukemia; cytotoxic; DNA-topoisomerase I inhibitors; antitumor agents; 7-trimethylsilyl-10-acetoxy camptothecin, 7-trimethylsilyl-11-fluoro camptothecin
11/08/2007US20070259904 Bi-aryl meta-pyrimidine inhibitors of kinases
1 ... 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 3522 3523 3524 3525 3526 3527 3528 3529 3530 ... 7860